GlassScriptPhysician profile
Scott Carmine Masullo
NPI 1568189322
$2,736.88
in general payments reported to CMS, 2019-2025
29 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.17 · 2023: $786 · 2024: $889 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.24 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $329.37 | 2022-2024 | Quviviq |
| Pfizer INC. | $309.14 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $271.41 | 2022-2025 | Seglentis, Zoryve, Livalo |
| Astrazeneca Pharmaceuticals LP | $234.19 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $221.39 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $109.10 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $106.88 | 2025 | Korlym |
| Lilly USA, LLC | $97.03 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $81.80 | 2023-2025 | Otezla, Repatha, Repatha |
| Almatica Pharma LLC | $69.40 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Kyowa Kirin, INC. | $54.45 | 2025 | |
| Bausch Health US, LLC | $50.82 | 2025 | Wellbutrin, Aplenzin |
| Dexcom, INC. | $39.48 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $35.00 | 2024 | Austedo Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.29 | 2023-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $32.04 | 2025 | Trintellix |
| Ironwood Pharmaceuticals, INC | $27.42 | 2023 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.66 | 2023 | Gvoke Hypopen |
| Biocryst US Sales Co., LLC | $17.97 | 2025 | Orladeyo |
| Astellas Pharma US INC | $17.93 | 2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $17.92 | 2023 | Evkeeza |
| Organon LLC | $17.77 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2024 | Xifaxan |
| Modernatx, INC. | $15.88 | 2025 | Mresvia |
| Ardelyx, INC. | $15.64 | 2023 | Ibsrela |
| Azurity Pharmaceuticals, INC. | $13.64 | 2024 | Edarbi |
| Axsome Therapeutics, INC. | $13.05 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Masullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.